- Trials with a EudraCT protocol (50)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
50 result(s) found for: Convulsive Therapy.
Displaying page 1 of 3.
EudraCT Number: 2021-002480-22 | Sponsor Protocol Number: TAK-935-3001 | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adul... | |||||||||||||
Medical condition: Dravet Syndrome (DS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA IT (Ongoing) FR (Ongoing) ES (Ongoing) LV (Ongoing) GR (Ongoing) NL (Ongoing) BE (Ongoing) PL (Ongoing) HU (Ongoing) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002484-25 | Sponsor Protocol Number: TAK-935-2002(OV935) | Start Date*: 2019-04-29 |
Sponsor Name:Takeda Development Center Americas, Inc. | ||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH ... | ||
Medical condition: Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: PT (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004396-12 | Sponsor Protocol Number: 02 | Start Date*: 2015-02-03 | |||||||||||
Sponsor Name:Azienda Ospedaliero-Universitaria Meyer | |||||||||||||
Full Title: Efficacy of ketamine in refractory convulsive status epilepticus in children: a multicenter, randomized, controlled, open-label, no-profit, with sequential design study. | |||||||||||||
Medical condition: Refractory convulsive status epilepticus, defined as the recurrence of crisis for more than 60 minutes and / or drug-resistant I l and II line. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004167-37 | Sponsor Protocol Number: ZX008-1502 | Start Date*: 2016-05-17 | |||||||||||
Sponsor Name:Zogenix International Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and You... | |||||||||||||
Medical condition: Dravet's syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) NO (Ongoing) DK (Completed) SE (Ongoing) ES (Completed) FR (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000474-38 | Sponsor Protocol Number: ZX008-1504 | Start Date*: 2016-09-13 | |||||||||||
Sponsor Name:Zogenix International Limited | |||||||||||||
Full Title: A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), ... | |||||||||||||
Medical condition: Dravet's syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002804-14 | Sponsor Protocol Number: ZX008-1503 | Start Date*: 2016-11-08 | |||||||||||
Sponsor Name:Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc | |||||||||||||
Full Title: An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome | |||||||||||||
Medical condition: Seizures associated with Dravet syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) IT (Completed) DK (Completed) ES (Ongoing) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000396-14 | Sponsor Protocol Number: 3/006/11 | Start Date*: 2011-06-15 | |||||||||||||||||||||
Sponsor Name:University of Aberdeen [...] | |||||||||||||||||||||||
Full Title: The use of Ketamine as an anaesthetic during electroconvulsive therapy (ECT) for depression: does it improve treatment outcome? | |||||||||||||||||||||||
Medical condition: Depression. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003425-30 | Sponsor Protocol Number: EPX-100-001 | Start Date*: 2022-07-27 |
Sponsor Name:Epygenix Therapeutics, Inc. | ||
Full Title: A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole HCl) as Adjunctive Therapy in Patients with Dravet Syndrome (ARGUS trial) | ||
Medical condition: Dravet Syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Temporarily Halted) HU (Ongoing) PL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017904-95 | Sponsor Protocol Number: P09-005 | Start Date*: 2010-06-28 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Upsher-Smith Laboratories, Inc. | ||||||||||||||||||||||||||||||||||||||
Full Title: Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures who had Participated in P09-004, a Randomized, Multicenter, Doub... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Refractory partial-onset seizures with or without secondary generalization | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016996-31 | Sponsor Protocol Number: P09-004 | Start Date*: 2010-06-28 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Upsher-Smith Laboratories, Inc. | ||||||||||||||||||||||||||||||||||||||
Full Title: A Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-O... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Refractory partial-onset seizures with or without secondary generalization | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001982-33 | Sponsor Protocol Number: E2090-E044-401 | Start Date*: 2005-09-05 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: An open label study of Zonegran (zonisamide) in patients with partial onset seizures. | |||||||||||||
Medical condition: Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) SE (Completed) DK (Completed) FI (Completed) DE (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005440-25 | Sponsor Protocol Number: SP904 | Start Date*: 2009-02-16 | ||||||||||||||||
Sponsor Name:UCB BIOSCIENCES, Inc. | ||||||||||||||||||
Full Title: A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures | ||||||||||||||||||
Medical condition: Partial-onset seizures (with and without secondary generalization) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) IE (Completed) ES (Completed) AT (Completed) DK (Completed) PT (Not Authorised) IT (Completed) FR (Completed) DE (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-003161-40 | Sponsor Protocol Number: A0081143 | Start Date*: 2007-12-14 | ||||||||||||||||
Sponsor Name:Pfizer Inc,East 42nd street,New york, NY10017, USA | ||||||||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTI-CENTER, COMPARATIVE, FLEXIBLE DOSE TRIAL OF PREGABALIN VERSUS GABAPENTIN AS ADJUNCTIVE THERAPY IN SUBJECTS WITH PARTIAL SEIZURES | ||||||||||||||||||
Medical condition: Adjunctive treatment for subjects with partial seizures, with or without secondary generalization. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Completed) ES (Completed) BG (Completed) SK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-004265-12 | Sponsor Protocol Number: NBI-921352-FOS2022 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with Focal Onset Seizures (FOS) | |||||||||||||
Medical condition: Focal Onset Seizures (FOS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) FR (Completed) HU (Prematurely Ended) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000607-33 | Sponsor Protocol Number: 200075 | Start Date*: 2019-06-18 |
Sponsor Name:GlaxoSmithKline S.A. | ||
Full Title: A Phase II, randomized, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK’s paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administer... | ||
Medical condition: Herpes Zoster Renal transplant Pediatric population | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001433-39 | Sponsor Protocol Number: NBI-921352-FOS2021 | Start Date*: 2021-09-08 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of NBI-921352 as Adjunctive Therapy in Adult Subjects ... | |||||||||||||
Medical condition: Focal Onset Seizures (FOS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) IT (Ongoing) BE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002142-31 | Sponsor Protocol Number: 547-SSE-301 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:Sage Therapeutics | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-547 INJECTION IN THE TREATMENT OF SUBJECTS WITH SUPER-REFRACTORY STATUS EPILEPTICUS | |||||||||||||
Medical condition: SUPER-REFRACTORY STATUS EPILEPTICUS (SRSE) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) SE (Completed) DK (Completed) ES (Completed) NL (Completed) FI (Completed) HU (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003385-24 | Sponsor Protocol Number: 2815 | Start Date*: 2016-09-28 |
Sponsor Name:GGZ inGeest, parner VUmc | ||
Full Title: The Recall-study: Rivastigmine for ECT-induced Cognitive Adverse effects in Late Life Depression: a multicenter, randomized, double-blind, placebo-controlled, crossover trial | ||
Medical condition: Interictal delirium during electric convulsive therapy- course | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001633-14 | Sponsor Protocol Number: CBD_DEE | Start Date*: 2020-03-05 | ||||||||||||||||
Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA | ||||||||||||||||||
Full Title: A single-centre, open-label pilot study to assess the efficacy and safety of CBD oral solution as an adjunctive treatment for pediatric subjects with Developmental and Epileptic Encephalopathy | ||||||||||||||||||
Medical condition: Developmental and Epileptic Encephalopathy (DEE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001324-36 | Sponsor Protocol Number: 1042-900 | Start Date*: 2015-06-05 | |||||||||||
Sponsor Name:Marinus Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children with PCDH19 Female Pediatric Epilepsy | |||||||||||||
Medical condition: PCDH19 Female Pediatric Epilepsy (FPE) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.